Robin Jones to Gastrointestinal Neoplasms
This is a "connection" page, showing publications Robin Jones has written about Gastrointestinal Neoplasms.
Connection Strength
3.870
-
KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. Chemotherapy. 2022; 67(2):81-90.
Score: 0.777
-
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 03; 145:132-142.
Score: 0.727
-
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future Oncol. 2020 Aug; 16(22):1639-1646.
Score: 0.697
-
Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: Clinical Outcome and Pathologic Features of a Molecularly Characterized Tertiary Center Case Series. Anticancer Res. 2018 03; 38(3):1479-1483.
Score: 0.595
-
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
Score: 0.189
-
Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. Eur J Surg Oncol. 2021 10; 47(10):2595-2601.
Score: 0.185
-
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol. 2020 10 01; 38(28):3294-3303.
Score: 0.176
-
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020 07; 21(7):935-946.
Score: 0.175
-
Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. JCO Glob Oncol. 2020 07; 6:1046-1051.
Score: 0.175
-
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 07; 21(7):923-934.
Score: 0.174